Amivantamab

The addition of amivantamab-vmjw to chemotherapy extended PFS among a subset of patients with non-small cell lung cancer, according to the agent’s manufacturer.

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.

Amivantamab-vmjw conferred long-term clinical response in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutations, according to data from the agent’s manufacturer.

In this video, Ravi Salgia, MD, PhD, highlighted two studies that investigated treatment for EGFR-mutated non-small cell lung cancer presented at ASCO Annual Meeting.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses treatment variations for rarer mutations such as EGFR exon 20 insertions.

The FDA approved amivantamab-vmjw for treatment of adults with non-small cell lung cancer who harbor EGFR exon 20 insertion mutations.

Amivantamab and lazertinib can be combined safely at their monotherapy doses for patients with advanced EGFR-mutated non-small cell lung cancer, according to results of the phase 1 CHRYSALIS study presented at ESMO Virtual Congress 2020.